Iconovo terminates liquidity provider agreement

ICORegulatoriskt pressmeddelande2026-06-29 14:00

Iconovo AB (publ) has decided to terminate its agreement with DNB Carnegie Investment Bank AB, which has acted as liquidity provider for the Company's shares.

The purpose of the liquidity provider arrangement has been to promote liquidity in trading of the Company's shares, reduce share price volatility and facilitate trading. Iconovo believes that liquidity in the Company's shares is satisfactory and that the need for a liquidity provider is therefore limited.

DNB Carnegie's assignment as liquidity provider will end after the close of trading on 30 June 2026.

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort®. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Tapper Partners AB.